File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0959-8049(01)00096-X
- Scopus: eid_2-s2.0-0035005243
- PMID: 11378338
- WOS: WOS:000169231700015
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer
Title | Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer |
---|---|
Authors | |
Keywords | c-erbB2 Comparative genomic hybridisation Immunohistochemistry Non-small cell lung cancer Tissue array |
Issue Date | 2001 |
Publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca |
Citation | European Journal Of Cancer, 2001, v. 37 n. 9, p. 1089-1095 How to Cite? |
Abstract | Overexpression of the c-erbB2 protein is observed in a variety of malignancies including non-small cell lung cancer (NSCLC). We aimed to determine the rate of c-erbB2-overexpression in our tumour collection and to clarify its correlation with the chromosomal status at the c-erbB2 locus 17q21 in NSCLC. Eighty-nine NSCLC were analysed immunohistochemically using a polyclonal c-erbB2 antibody (DAKO). The staining was scored according to the guidelines of the Clinical Trial Assay recommendations (0-3+). Of these, 44 cases were also analysed by comparative genomic hybridisation (CGH). Overexpression was observed in 37% of the cases (score > 1) which was associated with higher disease stages and a positive nodal status in adenocarcinomas. Chromosomal gains at 17q21 were clearly correlated with overexpression of the gene (P=0.009). In addition, there was a highly significant correlation between the c-erbB2 expression comparing the whole section immunostaining analysis and a 127 lung tumour tissue array which included 74 of the 89 cases that were analysed by the classical procedure. We conclude that c-erbB2 is a marker of tumour progression in NSCLC which can be observed on protein level and reflects chromosomal alterations at 17q21. © 2001 Elsevier Science Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/148229 |
ISSN | 2023 Impact Factor: 7.6 2023 SCImago Journal Rankings: 2.501 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Liu, S | en_HK |
dc.contributor.author | Tsang, BK | en_HK |
dc.contributor.author | Cheung, ANY | en_HK |
dc.contributor.author | Xue, WC | en_HK |
dc.contributor.author | Cheng, DKL | en_HK |
dc.contributor.author | Ng, TY | en_HK |
dc.contributor.author | Wong, LC | en_HK |
dc.contributor.author | Ngan, HYS | en_HK |
dc.date.accessioned | 2012-05-29T06:11:39Z | - |
dc.date.available | 2012-05-29T06:11:39Z | - |
dc.date.issued | 2001 | en_HK |
dc.identifier.citation | European Journal Of Cancer, 2001, v. 37 n. 9, p. 1089-1095 | en_HK |
dc.identifier.issn | 0959-8049 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/148229 | - |
dc.description.abstract | Overexpression of the c-erbB2 protein is observed in a variety of malignancies including non-small cell lung cancer (NSCLC). We aimed to determine the rate of c-erbB2-overexpression in our tumour collection and to clarify its correlation with the chromosomal status at the c-erbB2 locus 17q21 in NSCLC. Eighty-nine NSCLC were analysed immunohistochemically using a polyclonal c-erbB2 antibody (DAKO). The staining was scored according to the guidelines of the Clinical Trial Assay recommendations (0-3+). Of these, 44 cases were also analysed by comparative genomic hybridisation (CGH). Overexpression was observed in 37% of the cases (score > 1) which was associated with higher disease stages and a positive nodal status in adenocarcinomas. Chromosomal gains at 17q21 were clearly correlated with overexpression of the gene (P=0.009). In addition, there was a highly significant correlation between the c-erbB2 expression comparing the whole section immunostaining analysis and a 127 lung tumour tissue array which included 74 of the 89 cases that were analysed by the classical procedure. We conclude that c-erbB2 is a marker of tumour progression in NSCLC which can be observed on protein level and reflects chromosomal alterations at 17q21. © 2001 Elsevier Science Ltd. | en_HK |
dc.language | eng | en_US |
dc.publisher | Pergamon. The Journal's web site is located at http://www.elsevier.com/locate/ejca | en_HK |
dc.relation.ispartof | European Journal of Cancer | en_HK |
dc.subject | c-erbB2 | en_HK |
dc.subject | Comparative genomic hybridisation | en_HK |
dc.subject | Immunohistochemistry | en_HK |
dc.subject | Non-small cell lung cancer | en_HK |
dc.subject | Tissue array | en_HK |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 And Over | en_US |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung - Genetics - Metabolism - Pathology | en_US |
dc.subject.mesh | Chromosomes, Human, Pair 17 - Genetics | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gene Expression | en_US |
dc.subject.mesh | Genome, Human | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunohistochemistry | en_US |
dc.subject.mesh | Lung Neoplasms - Genetics - Metabolism - Pathology | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle Aged | en_US |
dc.subject.mesh | Neoplasm Proteins - Metabolism | en_US |
dc.subject.mesh | Ploidies | en_US |
dc.subject.mesh | Receptor, Erbb-2 - Metabolism | en_US |
dc.title | Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Liu, S:stephasl@hku.hk | en_HK |
dc.identifier.email | Cheung, ANY:anycheun@hkucc.hku.hk | en_HK |
dc.identifier.email | Ngan, HYS:hysngan@hkucc.hku.hk | en_HK |
dc.identifier.authority | Liu, S=rp00372 | en_HK |
dc.identifier.authority | Cheung, ANY=rp00542 | en_HK |
dc.identifier.authority | Ngan, HYS=rp00346 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0959-8049(01)00096-X | en_HK |
dc.identifier.pmid | 11378338 | - |
dc.identifier.scopus | eid_2-s2.0-0035005243 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0035005243&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 37 | en_HK |
dc.identifier.issue | 9 | en_HK |
dc.identifier.spage | 1089 | en_HK |
dc.identifier.epage | 1095 | en_HK |
dc.identifier.isi | WOS:000169231700015 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Liu, S=37102450400 | en_HK |
dc.identifier.scopusauthorid | Tsang, BK=7007086513 | en_HK |
dc.identifier.scopusauthorid | Cheung, ANY=54927484100 | en_HK |
dc.identifier.scopusauthorid | Xue, WC=7103165268 | en_HK |
dc.identifier.scopusauthorid | Cheng, DKL=7402806161 | en_HK |
dc.identifier.scopusauthorid | Ng, TY=7402229853 | en_HK |
dc.identifier.scopusauthorid | Wong, LC=7402092003 | en_HK |
dc.identifier.scopusauthorid | Ngan, HYS=34571944100 | en_HK |
dc.identifier.issnl | 0959-8049 | - |